Novavax Global Commercial Operations and COVID-19 Vaccine Update

Novavax prototype booster provides robust breadth of immunity Anti-rS IgG GMT (EU/mL) with 95% CI novavax 100,000 10,000 1,000 100 263,387 161,258 117,411 85,189 52,559 39,307 127,913 95% VE* 43,548 33,685 88% VE* 10 Novavax x2 Moderna x3 Pfizer x3 + Novavax x2 Moderna x3 + Novavax + Novavax Novavax + Novavax + Novavax Pfizer x3 + Novavax Novavax x2 Moderna x3 + Novavax Anti-Prototype *Inferred from the CoP established from prototype data to emerging variants (BA.1 and BA.5) Novavax x2 + Novavax = 7; Moderna x3 + Novavax = 60; Pfizer x3 + Novavax = 58 to 60 Anti-BA.1 + Novavax Anti-BA.5 Pfizer x3 + Novavax © 2023 NOVAVAX. All rights reserved. 50

View entire presentation